Trends

AYUSH Ministry Banned the Promotion of Patanjali’s Coronil Drug! No Mention of COVID-19 in Patanjali’s License application?

Patanjali launched a special Corona kit on Tuesday, claiming it is India’s first Ayurvedic medicine for COVID-19 treatment. They said that during clinical trials; the drug showed 100% excellent results on sufferers at Patanjali Yogpeeth in Haridwar.

After the news about the COVID remedy spread, the AYUSH department took aware of the reports and informed that the department did not get the facts and details of the announced scientific research.

The Ministry of AYUSH issued a statement asserting that for this, Patanjali Ayurved Limited has been ordered to provide all the details of Coronil drug consent. It has also instructed that until the investigation is complete, the company should stop advertising/promoting claims related to coronavirus medicine.

Therefore, Patanjali has been further informed that, due to the prevalence of pandemic COVID-19, any advertisements of any drugs for the treatment of COVID-19 (including Ayurvedic drugs) are controlled under the provision of the Drug Act and “Incredible Remedies (Objective Advertisements)” Act 1954 and by the Central Government’s Rules and Instructions.

The AYUSH ministry also ordered Patanjali not to sell its coronavirus’ drugs until the necessary approval from the ministry is obtained.

What details must be provided?

Patanjali has been demanded to submit reports to the Ministry about

  • Evidence of the facts, statements, and claims related to Coronil, the names, and compositions of the medicines being effective in the treatment of coronavirus infection.
  • The name of the sites/hospitals where the study was conducted for COVID 19.
  • Provide all detailed information to the government, including the protocol, sample size, Institutional Ethics Committee approval, CTRI registration center, and research results’ data.
  • Ayush Ministry also demanded the license and endorsement details of the product.

    According to sources, government officials of Uttarakhand told that Patanjali Ayurved Ltd, promoted by yoga master Ramdev, did not mention that drug of coronavirus disease was being developed by them while applying for a license.

The government of Uttarakhand, the state licensing authority for Haridwar based Patanjali, has approved the production and sale of the drug.

A permit official from the Ayurveda department of the state said: “At Patanjali’s request, we granted them a permit. They did not mention the coronavirus. We only approved the license for boosting immunity, coughing, and fever License.” 

The official added: “We will send them a notice ordering them how could they obtained permission to manufacture the COVID-19 kit.”

The ministry also urged the state licensing authority of the Uttarakhand government to provide a copy of the Ayurvedic therapy license and product endorsement details that have proven to be effective in treating COVID 19.

The CEO of Patanjali Ayurved announced on Tuesday that the company has provided all information about the newly released Covid-19 drug to the Ministry of AYUSH. Acharya Balkrishna said on Twitter.

“The government encourages and makes the Ayurveda community proud. The communication gap has been done away with, and we have achieved 100% of all the standard parameters of Randomized Placebo-Controlled Clinical Trials. We have provided relevant information to the AYUSH Department for the same,” Balkrishna tweeted.

One of the Ministers also said that after reviewing its report, the AYUSH Department will clarify its position on Patanjali’s “Coronil and Swasari” claiming to cure the coronavirus. Till then, the government announced that companies were not allowed to promote/advertising any drug for the treatment of Corona infection without government approval.
If the statement given by Uttarakhand Official is true, then the question is Why Patanjali did not mention coronavirus while applying for COVID-19 drug’s License? Are they putting the life of Million people at risk by offering this drug?

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker